Updated on 24 August 2026
针对癌症和感染的新型免疫治疗药物
Commercial Director at Centre for Virology, Vaccinology and Therapeutics Limited
China (Hong Kong)
About
Δ42PD-1是PD-1的一种亚型,具有独特的化学特性,不与癌细胞上通常与PD-1结合的PD-L1配体相互作用。通过特异性识别并结合 T 细胞表面的 Δ42PD1,精准阻断其与癌细胞表面 TLR4 的异常信号通路,直击耐药根源。有效抑制促瘤炎症因子(如 IL-6)的释放,逆转T 细胞耗竭状态,恢复其正常的肿瘤杀伤功能。从根源上解决传统 PD-1 疗法诱导的耐药问题,有望将免疫治疗有效人群从 20% 大幅提升,实现对耐药肿瘤的有效清除。
Project Location
- China (Hong Kong)
Project Format
- Private Project
Go Global Project
- Yes
ESG (Environmental, Social, and Governance)
- Yes
Project Stage
- Feasibility Study Completed
Main Project Sector
- Technology
Technology
- Bio-Tech
- Health Technology
- Medical Technology
Total Project Value
- 25,000,001 to 50,000,000 USD
Investment Capital Required
- 5,000,001 to 7,500,000 USD
Interested Format of Cooperation
- Open for Negotiation
Preferred Financing Model
- Equity
Type(s) of Last Financing Round of the project (if Applicable)
- Equity (private)
Main Service(s) Required
- Financial Services
Financial Services
- Private Equity & Venture Capital
Attached files
Similar opportunities
Project
- Yes
- Yes
- Equity
- Bio-Tech
- Technology
- Private Project
- Health Technology
- Equity (private)
- Medical Technology
- Financial Services
- Direct Equity Investment
- 5,000,001 to 7,500,000 USD
- 25,000,001 to 50,000,000 USD
- Investment / Financing Discussion
Roger Zhang
Commercial Director at Centre for Virology, Vaccinology and Therapeutics Limited
China (Hong Kong)
Project
通用型人类多能干细胞来源胰岛类器官糖尿病根治性疗法 (Off-the-shelf Stem Cell-derived Islet Organoid Therapy for Diabetes Cure)
- No
- Yes
- Equity
- Technology
- Equity (private)
- Financial Services
- Professional Services
- Minority Shareholdings
- Direct Equity Investment
- 25,000,001 to 50,000,000 USD
- 25,000,001 to 50,000,000 USD
- Investment / Financing Discussion
- Public-Private Partnership Project
Yi HE
CTO at 周易生物
China (Hong Kong)
Project
通用型人类多能干细胞来源胰岛类器官糖尿病根治性疗法 (Off-the-shelf Stem Cell-derived Islet Organoid Therapy for Diabetes Cure)
- No
- Yes
- Equity
- Bio-Tech
- Technology
- IP Related
- Legal Advisory
- Equity (private)
- Medical Technology
- Financial Services
- Financial Advisory
- Professional Services
- Minority Shareholdings
- Corporate Intelligence
- Direct Equity Investment
- Institutional Investment
- 2,500,001 to 5,000,000 USD
- 25,000,001 to 50,000,000 USD
- Private Equity & Venture Capital
- Investment / Financing Discussion
- Public-Private Partnership Project
彬 杨
CEO at 周易生物
China (Hong Kong)